Northerner
Admin (Retired)
- Relationship to Diabetes
- Type 1
Novo Nordisk A/S (NVO - Analyst Report) announced data from new analyses of the phase IIIa DUAL studies (DUAL I and DUAL II) on Xultophy. Data showed that after four weeks from the initiation of treatment, Xultophy (a once-daily single injection combination of Tresiba and Victoza) led to more rapid and substantial improvement in glycemic control along with a beneficial weight profile in type II diabetes patients (insulin-naive as well as those treated with insulin previously), compared to the individual administration of Tresiba and Victoza.
At week-4 in the DUAL I study, a higher proportion of patients achieved fasting plasma glucose of ≤7.2 mmol/L under treatment with Xultophy (76%) than patients treated with Tresiba or Victoza (62% each). Moreover, 57% of the Xultophy-treated patients achieved glycated hemoglobin (HbA1c) of less than 7% at week-8 compared to 38% and 47% of those treated with Tresiba and Victoza, respectively.
Additionally, Novo Nordisk said that Xultophy-treated patients were more likely to reach pre-prandial (before meal) and post-prandial (after meal) blood glucose targets compared to either Tresiba or Victoza.
http://www.zacks.com/stock/news/148028/novo-nordisk-reveals-fresh-data-on-xultophy-for-diabetes
At week-4 in the DUAL I study, a higher proportion of patients achieved fasting plasma glucose of ≤7.2 mmol/L under treatment with Xultophy (76%) than patients treated with Tresiba or Victoza (62% each). Moreover, 57% of the Xultophy-treated patients achieved glycated hemoglobin (HbA1c) of less than 7% at week-8 compared to 38% and 47% of those treated with Tresiba and Victoza, respectively.
Additionally, Novo Nordisk said that Xultophy-treated patients were more likely to reach pre-prandial (before meal) and post-prandial (after meal) blood glucose targets compared to either Tresiba or Victoza.
http://www.zacks.com/stock/news/148028/novo-nordisk-reveals-fresh-data-on-xultophy-for-diabetes